Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trialAditya H. Gaur, R. Kiplin Guy, John Woodford et al.|The Lancet Infectious Diseases|2020Cited by 77
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug developmentAditya H. Gaur, R. Kiplin Guy, John C. Panetta et al.|EBioMedicine|2022Cited by 17